Evidence map›Paper›PMID 37797300›Full record

ArticleEuropean journal of neurology2024

Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.

Salvatore Mazzeo, Assunta Ingannato, Giulia Giacomucci, Alberto Manganelli, Valentina Moschini, Juri Balestrini, Arianna Cavaliere, Carmen Morinelli, Giulia Galdo, Filippo Emiliani and 10 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07402161 (Unraveling the SIGNature of ALzheimer's Disease), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07402161 recruitingnot on this mapstarted 2025, after this paper: background citation

Unraveling the SIGNature of ALzheimer's Disease: Integrating Multimodal Biomarkers Through Machine Learning

TypeobservationalSponsorIRCCS Policlinico S. DonatoRan2025 to 2028Enrolled250ConditionsSubjective Cognitive Decline (SCD), Subjective Cognitive Complaints (SCCs), Subjective Cognitive Impairment, Subjective Cognitive Concerns
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. A blood based mitochondrial functional index biomarker for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Salvatore MazzeoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.ORCID 0000-0001-5985-5060
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Alberto ManganelliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Valentina MoschiniResearch and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Juri BalestriniDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Arianna CavaliereDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Carmen MorinelliResearch and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Giulia GaldoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Filippo EmilianiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Diletta PiazzesiResearch and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Chiara CrucittiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Daniele FrigerioDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Cristina PolitoIRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
Valentina BertiDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.ORCID 0000-0001-9947-6559
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Sonia PadiglioniResearch and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Sandro SorbiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.ORCID 0000-0002-6176-3584
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · ITDon Carlo Gnocchi Foundation · ITEuropean Society for Sexual Medicine · IT

Funding

Ministero della SaluteRegione Toscana
6 · The paper itself

Abstract

background and purposeWe aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).

methodsThis longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and

resultsAt baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (area under the curve [AUC] 0.82). We identified cut-off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (progressive SCD [p-SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p-MCI]). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p-MCI (3.52 ± 4.06 pg/mL) compared to non-progressive SCD (0.81 ± 1.25 pg/mL) and non-progressive MCI (-0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954).

conclusionPlasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease.

Indexed as

Alzheimer DiseaseCognitive DysfunctionNeurofilament ProteinsAmyloid beta-PeptidesBiomarkersCross-Sectional StudiesDisease ProgressionHumansIntermediate FilamentsLongitudinal Studiestau ProteinsAmyloid beta-PeptidesBiomarkersneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer's diseasebiomarkerdementiamild cognitive impairmentneurofilament

Identifiers

PMID37797300
PMCPMC11235835
OpenAlexW4387392065

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.